Recent Pfizer Press Releases

  • 2/6/08 6:00 pm EST

    New Data on Investigational HIV/AIDS Compounds Presented;

    Phase III Data Reinforce Selzentry Efficacy

    BOSTON--(BUSINESS WIRE)--At this week’s major HIV/AIDS research meeting, Pfizer presented new data on two investigational second generation HIV compounds – a CCR5 antagonist and a non-nucleoside reverse transcriptase inhibitor (NNRTI). Pfizer also presented additional data on SelzentryTM (maraviroc) tablets, its first-in-class medicine approved last year for use in treatment-experienced HIV patients infected with a certain type ofmore...
  • 1/28/08 8:10 pm EST

    The First Oral Smoking Cessation Aid in Japan

    TOKYO--(BUSINESS WIRE)--Pfizer Japan Inc (headquarter in Shibuya-ku, Tokyo; headed by President & Chief Executive Officer, Hiromitsu Iwasaki; and capitalized at Yen 64.8 billion) announced that on January 25, the company received manufacturing and marketing authorization for Champix® Tablet 0.5 mg/1mg (varenicline tartrate), a smoking cessation aid for smokers dependent on nicotine. Champix is Japan’s first oral smokingmore...
  • 1/23/08 8:00 am EST
    • Fourth-Quarter 2007 Revenues of $13.1 Billion Increased from $12.6 Billion in the Year-Ago Quarter
    • Fourth-Quarter 2007 Reported Diluted EPS of $0.42 Compared with $1.32 in the Year-Ago Quarter, which Included the $1.08 EPS Gain on the Sale of the Consumer Healthcare Business
    • Fourth-Quarter 2007 Adjusted Diluted EPS(1) of $0.52 Increased from $0.43 in the Year-Ago Quarter
    • Full-Year 2007 Revenues of $48.6 Billion Increased from $48.4 Billion in 2006
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE): ($ in millions, except per share amounts)   Fourth Quarter   Full Year   2007   2006   Changemore...
  • 1/22/08 6:00 am EST

    With Millions of U.S. Dogs Overweight or Obese, and Most Owners Unaware of the Problem, Veterinarians Lend Helping Hand With First-Ever National Canine Weight Check This February

    NEW YORK--(BUSINESS WIRE)--As millions of Americans vow to get healthier and stave off illness by making a New Year’s resolution to lose weight, it’s time for dog owners to make a similar pledge for their furry friends. Recent studies indicate that 25 to 40 percent of U.S. dogs – approximately 17 million – are overweight or obese and potentially facing serious health problems. What’s more troubling is thatmore...
  • 1/18/08 11:25 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts being held on Wednesday, March 5, at 8:30a.m. Eastern Standard Time. The purpose of the meeting is to discuss the Company’s strategic direction. Jeffrey B. Kindler, Pfizer chairman and chief executive officer, will host the meeting. To view and listen to the webcast, visit our web sitemore...
  • 1/18/08 8:30 am EST
    NEW YORK--(BUSINESS WIRE)--Cigarette smoking is associated with significant morbidity and mortality. Smoking is the leading preventable cause of disease and premature death in the United States, with more than 438,000 U.S. deaths annually attributable to smoking. Patients who smoke cigarettes should be counseled to quit. CHANTIX® was approved in May of 2006 in the U.S. as an aid to smoking cessation. Based upon post-marketing reportsmore...
  • 1/16/08 12:04 pm EST

    Pfizer Partners With 17 Nonprofit Organizations Sending 28 Fellows to Help Address Systemic Health Care Challenges in the Developing World

    NEW YORK--(BUSINESS WIRE)-- Pfizer Inc today announced the eighth class of Global Health Fellows, a group of 28 Pfizer colleagues from North America, Europe and Asia, who will partner with non-governmental organizations (NGOs) and multilateral organizations (MLOs) in developing countries to help build health care infrastructure while on dedicated 4-6 month assignments. The Pfizer Global Health Fellows program is one of the first public-more...
  • 1/16/08 11:38 am EST
    NEW YORK--(BUSINESS WIRE)--The early addition of Lipitor® (atorvastatin calcium) Tablets to effective blood pressure lowering treatment maintained a significant 36 percent reduction in the relative risk of fatal or non-fatal heart attacks over five years, according to a new analysis. This was a post-hoc analysis (designed and completed following the closure of the trial) of the lipid-lowering arm of the Anglo-Scandinavian Cardiacmore...
  • 1/16/08 4:00 am EST
    NEW YORK & MARTINSRIED, Germany--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) and Scil Technology GmbH (Scil) have signed a licensing agreement for worldwide collaboration on Scil’s cartilage specific growth factor CD-RAP. Under this agreement, Pfizer will obtain a worldwide exclusive license to develop and commercialize CD-RAP. In addition to receiving royalties on the sale of any products that may be commercialised under this agreement, Scil is eligiblemore...
  • 1/15/08 9:00 am EST
    NEW YORK--(BUSINESS WIRE)--European vets are about to be given the same powerful medical tool which has helped U.S. vets manage obese dogs who don’t respond to exercise and diet. Since Pfizer Animal Health’s SLENTROLTM was introduced eight months ago in the U.S., thousands of obese dogs have benefited from healthier weights and more active lives. Now, European vets will be able to talk to dog owners about Slentrol asmore...